Athira priced its IPO on Thursday at $17 per share, which came in at the high end of its range.The company sold 12 million shares and raised $204 million in the IPO. The stock was up slightly in ...

BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal ...

However, Athira said ADAS-Cog11 and ADCS-ADL23 “directionally favored fosgonimeton treatment,” with a nonsignificant difference of 0.70 on the cognition scale and 0.67 on the function score.

BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal ...

Just a couple of weeks after announcing that its Alzheimer’s disease candidate fosgonimeton failed to beat placebo in a phase 2/3 trial, Athira is laying off 70% of its staff and saying goodbye ...

Athira Pharma (NASDAQ:ATHA) shares fell over 75% after the company said fosgonimeton, its experimental therapy for Alzheimer's disease, failed in a Phase 2/3 trial, prompting at least two Wall ...

Athira Pharma Inc. will proceed in 2023 with several clinical trials for treatments for Alzheimer’s disease, Parkinson’s disease and ALS, the biopharmaceutical company announced in a press ...

The move follows months of inquiry during which the former Athira CEO was placed on temporary leave. Athira grant used doctor's credentials without his knowledge Questions around Athira echo ...